Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,035 active trials28 approved drugs633 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,615 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT00003875 | Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 5, 2017 |
| clinicaltrials |
| NCT01158118 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01457885 | Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen(CloBu4) | completed | Phase 2 | 75 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | terminated | Phase 2 | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00708721 | Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 11 | University of UtahOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00448201 | Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease | completed | Phase 2 | 71 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00589602 | T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases | terminated | Phase 2 | 13 | The Cleveland ClinicOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT01323920 | Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors | completed | Phase 2 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation | terminated | Phase 2 | 12 | St. Jude Children's Research HospitalOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00450983 | Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | terminated | Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00555048 | Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01083706 | Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00863434 | Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | May 15, 2017 | clinicaltrials |
| NCT00997243 | Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes | terminated | Phase 2 | 7 | Alison WalkerOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01435343 | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | completed | Phase 1 / Phase 2 | 55 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02520102 | Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia | withdrawn | Phase 2 | 0 | SanofiINDUSTRY | 0 | Apr 20, 2017 | clinicaltrials |
| NCT00923910 | Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Apr 12, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT01465386 | Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission | terminated | Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT03080922 | High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01607645 | Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | terminated | Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01118013 | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant | terminated | Phase 2 | 6 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 24, 2017 | clinicaltrials |
| NCT00587054 | Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders | completed | Phase 2 | 129 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00321932 | Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | University of MinnesotaOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00195104 | Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML | completed | Phase 1 / Phase 2 | 87 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT02125318 | A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders | completed | Phase 2 | 18 | Galena Biopharma, Inc.INDUSTRY | 1 | Feb 27, 2017 | clinicaltrials |
| NCT00171912 | Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes | completed | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT00880269 | Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 23, 2017 | clinicaltrials |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | terminated | Phase 2 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01843179 | Sulindac for Patients With AML | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00475150 | Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01567059 | Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 | 34 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053206 | A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia | unknown | Phase 2 | 84 | All India Institute of Medical SciencesOTHER | 0 | Feb 15, 2017 | clinicaltrials |
| NCT00394381 | Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 17 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00815321 | Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy | completed | Phase 2 | 11 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03045627 | Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients | unknown | Phase 2 | 120 | Shandong UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT00313586 | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 2 | 197 | National Cancer Institute (NCI)NIH | 1 | Feb 2, 2017 | clinicaltrials |
| NCT01810120 | Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | completed | Phase 1 / Phase 2 | 30 | Mariella EnocOTHER | 1 | Jan 23, 2017 | clinicaltrials |
| NCT01709396 | ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS(ED-TBI) | suspended | Phase 2 | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT01520805 | Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | withdrawn | Phase 2 | 0 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Dec 29, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2017source: clinicaltrials